In PDAC, KRAS inhibitors can partially remodel the microenvironment by reducing myeloid cell accumulation, increasing CD8+ T-cell infiltration, and reprogramming cancer-associated fibroblasts (Mahadevan et al., 2023). This evidence concerns the gene KRAS and cancer.